BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yu F, Bonaventure P, Thurmond RL. The Future Antihistamines: Histamine H3 and H4 Receptor Ligands. In: Thurmond RL, editor. Histamine in Inflammation. Boston: Springer US; 2010. pp. 125-40. [DOI: 10.1007/978-1-4419-8056-4_12] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Vardanyan R, Hruby V. Antihistamine Drugs. Synthesis of Best-Seller Drugs. Elsevier; 2016. pp. 247-63. [DOI: 10.1016/b978-0-12-411492-0.00016-x] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
2 Ahmad SF, Ansari MA, Zoheir KM, Bakheet SA, Korashy HM, Nadeem A, Ashour AE, Attia SM. Regulation of TNF-α and NF-κB activation through the JAK/STAT signaling pathway downstream of histamine 4 receptor in a rat model of LPS-induced joint inflammation. Immunobiology 2015;220:889-98. [DOI: 10.1016/j.imbio.2015.01.008] [Cited by in Crossref: 65] [Cited by in F6Publishing: 64] [Article Influence: 9.3] [Reference Citation Analysis]
3 Simons FER, Simons KJ. Histamine and H1-antihistamines: Celebrating a century of progress. Journal of Allergy and Clinical Immunology 2011;128:1139-1150.e4. [DOI: 10.1016/j.jaci.2011.09.005] [Cited by in Crossref: 282] [Cited by in F6Publishing: 209] [Article Influence: 25.6] [Reference Citation Analysis]
4 Cowden JM, Yu F, Challapalli M, Huang JF, Kim S, Fung-Leung WP, Ma JY, Riley JP, Zhang M, Dunford PJ, Thurmond RL. Antagonism of the histamine H4 receptor reduces LPS-induced TNF production in vivo. Inflamm Res 2013;62:599-607. [PMID: 23532396 DOI: 10.1007/s00011-013-0612-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
5 Fitzsimons R, van der Poel LA, Thornhill W, du Toit G, Shah N, Brough HA. Antihistamine use in children. Arch Dis Child Educ Pract Ed 2015;100:122-31. [PMID: 25147323 DOI: 10.1136/archdischild-2013-304446] [Cited by in Crossref: 41] [Cited by in F6Publishing: 30] [Article Influence: 5.1] [Reference Citation Analysis]
6 Funke U, Vugts DJ, Janssen B, Spaans A, Kruijer PS, Lammertsma AA, Perk LR, Windhorst AD. 11 C-labeled and 18 F-labeled PET ligands for subtype-specific imaging of histamine receptors in the brain: PET ligands for histamine receptors in the brain. J Label Compd Radiopharm 2013;56:120-9. [DOI: 10.1002/jlcr.3038] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
7 Geyer R, Nordemann U, Strasser A, Wittmann HJ, Buschauer A. Conformational Restriction and Enantioseparation Increase Potency and Selectivity of Cyanoguanidine-Type Histamine H4 Receptor Agonists. J Med Chem 2016;59:3452-70. [PMID: 27007611 DOI: 10.1021/acs.jmedchem.6b00120] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
8 Ehling S, Butler A, Thi S, Ghashghaei HT, Bäumer W. To scratch an itch: Establishing a mouse model to determine active brain areas involved in acute histaminergic itch. IBRO Rep 2018;5:67-73. [PMID: 30364768 DOI: 10.1016/j.ibror.2018.10.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Sadek B, Alisch R, Buschauer A, Elz S. Synthesis and dual histamine H₁ and H₂ receptor antagonist activity of cyanoguanidine derivatives. Molecules 2013;18:14186-202. [PMID: 24248146 DOI: 10.3390/molecules181114186] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]